Cold Spring Harbor, NY — Cancer is relentless and resilient. When a drug blocks a cancer cell’s main survival pathway, the cell avoids the obstacle by taking different pathways or detours to save itself. This tactic is called “developing resistance,” and it’s one of the key challenges researchers face when seeking effective therapeutics to combat pancreatic ductal adenocarcinoma (PDA).
A group of researchers at Cold Spring Harbor Laboratory (CSHL) has now found a way to tackle this problem and stop the growth of pancreatic tumors in mice. Their findings are published in the journal Clinical Cancer Research.
Pancreatic cancer has a five-year survival rate of only 8 percent. Professor David Tuveson’s lab at CSHL is focused on identifying better treatment strategies to help prolong survival for patients, including new drugs that can be introduced into clinical trials.
More than 90 percent of pancreatic cancer patients carry a mutation, which controls cell growth and death, in the cancer-causing gene KRAS. The KRAS oncogene is difficult to drug directly, so researchers are testing indirect routes to shutting it down. One approach targets the AKT and MAP-Kinase (MAPK) downstream signaling pathways that support KRAS.
“Some clinical trials have targeted these pathways, but high toxicity levels and therapeutic resistance development precluded further investigation of these regimens,” said Youngkyu Park, a Research Investigator in the Tuveson lab. “Toxicity can occur when anti-tumor agents aren’t malignancy-specific. That means they risk killing healthy cells as well.”
The Tuveson lab encountered the problem of resistance pathways when it tried to barricade both the AKT and MAPK pathways in PDA.
To develop an effective cancer drug, the team created drug cocktails that block both the main pathways supporting pancreatic cancer cell growth and cancer cell-specific resistance pathways.
By culturing normal human cells and cancer cells in 3D organoid models and testing them concurrently, the team was able to distinguish particular signaling mechanisms that only affected pancreatic cancer cells. This allowed them to pinpoint the ERBB signaling pathway as the pancreatic cancer-specific resistance mechanism following AKT/MAPK blockade.
By inhibiting ERBB signaling in addition to MAPK signaling, the researchers observed pancreatic tumors shrink in organoid mouse model of PDA.
“We hope this study will help other research groups to use the same methodological approach we use in the paper,” said Mariano Ponz-Sarvisé, a former CSHL Clinical Fellow and an author on the study. “I believe that for some drugs, this approach can help find new avenues to overcome resistance.”
This research was funded by the Lustgarten Foundation, the Cold Spring Harbor Laboratory Association, Stand Up To Cancer, the STARR Foundation, the Associazione Italiana Ricerca sul Cancro, Sociedad Española de Oncología Médica, the Swedish Research Council, The Kempe Foundations, the Swedish Society of Medicine, the Damon Runyon Cancer Research Foundation, and the NIH.
Ponz-Sarvise et. al, “Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer” appeared in Clinical Cancer Research on September 9, 2019.
Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,100 people including 600 scientists, students and technicians. The Meetings & Courses Program annually hosts more than 12,000 scientists. The Laboratory’s education arm also includes an academic publishing house, a graduate school and the DNA Learning Center with programs for middle and high school students and teachers. For more information, visit www.cshl.edu
Roy J. Zuckerberg Professor of Cancer Research
M.D., Ph.D., Johns Hopkins University, 1994